全文获取类型
收费全文 | 243篇 |
免费 | 30篇 |
国内免费 | 3篇 |
专业分类
儿科学 | 38篇 |
妇产科学 | 1篇 |
基础医学 | 17篇 |
临床医学 | 10篇 |
内科学 | 47篇 |
特种医学 | 3篇 |
外科学 | 9篇 |
综合类 | 21篇 |
预防医学 | 1篇 |
药学 | 41篇 |
中国医学 | 1篇 |
肿瘤学 | 87篇 |
出版年
2023年 | 3篇 |
2022年 | 6篇 |
2021年 | 10篇 |
2020年 | 9篇 |
2019年 | 8篇 |
2018年 | 9篇 |
2017年 | 11篇 |
2016年 | 7篇 |
2015年 | 9篇 |
2014年 | 10篇 |
2013年 | 28篇 |
2012年 | 6篇 |
2011年 | 15篇 |
2010年 | 10篇 |
2009年 | 13篇 |
2008年 | 10篇 |
2007年 | 5篇 |
2006年 | 6篇 |
2005年 | 12篇 |
2004年 | 6篇 |
2003年 | 8篇 |
2002年 | 10篇 |
2001年 | 11篇 |
2000年 | 15篇 |
1999年 | 2篇 |
1998年 | 4篇 |
1997年 | 5篇 |
1996年 | 1篇 |
1995年 | 3篇 |
1994年 | 4篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1988年 | 5篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1982年 | 1篇 |
排序方式: 共有276条查询结果,搜索用时 31 毫秒
81.
82.
一种新型海洋来源的蒽环类化合物D19抗肿瘤活性及机制研究 总被引:1,自引:0,他引:1
目的探讨新型海洋源性蒽环类化合物D19的抗肿瘤作用及分子机制。方法采用四甲基二氮唑蓝(MTT)比色法、脱氧核糖核酸末端转移酶介导的缺口末端标记法(TUNEL)、免疫印迹法(WesternBlotting)检测D19对人乳腺癌细胞系MCF-7和MDA-MB-435生长的影响及相关信号通路蛋白的变化。结果 D19对MCF-7、MDA-MB-435的半数抑制浓度(IC50)分别为4.01μmol/L和7.32μmol/L;D19具有有效诱导人乳腺癌细胞凋亡的作用;Western Blotting结果显示D19作用后细胞中的凋亡蛋白如caspase9以及下游的效应蛋白PARP都发生裂解。结论从细胞水平和分子水平证明新型海洋源性蒽环类化合物D19具有很强的抗乳腺癌活性,有可能发展成为治疗乳腺癌等其他实体肿瘤的先导化合物。 相似文献
83.
《Bulletin du cancer》2010,97(6):687-691
We describe herein the current concepts tested in clinical trials dedicated to patients with metastatic soft tissue sarcomas: identify predictive factors under anthracyclin-based regimens, identify patients beneficing from polychemotherapy, benefit of maintenance treatment, use of non-progression rate rather than response rate for selecting new drugs, histology-tailored or biological target-tailored second-line treatment. 相似文献
84.
Anticancer drugs generally have intracellular targets, implicating transport over the plasma membrane. For amphiphilic agents, such as the anthracycline doxorubicin, this occurs by passive diffusion. We investigated whether exogenous membrane-permeable lipid analogues improve this drug influx. Combinations of drugs and lipid analogues were coadministered to cultured endothelial cells and various tumour cell lines, and subsequent drug accumulation in cells was quantified. We identified N-hexanoyl-sphingomyelin (SM) as a potent enhancer of drug uptake. Low micromolar amounts of this short-chain sphingolipid, being not toxic itself, enhanced the uptake of doxorubicin up to 300% and decreased its EC(50) toxicity values seven- to 14-fold. N-hexanoyl SM acts at the level of the plasma membrane, but was found not incorporated in (isolated) lipid rafts, and artificial disruption or elimination of raft constituents did not affect its drug uptake-enhancing effect. Further, any mechanistic role of the endocytic machinery, membrane leakage or ABC-transporter-mediated efflux could be excluded. Finally, a correlation was established between the degree of drug lipophilicity, as defined by partitioning in a two-phase octanol-water system, and the susceptibility of the drug towards the uptake-enhancing effect of the sphingolipid. A clear optimum was found for amphiphilic drugs, such as doxorubicin, epirubicin and topotecan, indicating that N-hexanoyl-SM might act by modulating the average degree of plasma membrane lipophilicity, in turn facilitating transbilayer drug diffusion. The concept of short-chain sphingolipids as amphiphilic drug potentiators provides novel opportunities for improving drug delivery technologies. 相似文献
85.
Icli F Akbulut H Uner A Yalcin B Baltali E Altinbas M Coşkun S Komurcu S Erkisi M Demirkazik A Senler FC Sencan O Büyükcelik A Boruban C Onur H Zengin N Sak SD 《British journal of cancer》2005,92(4):639-644
Our objective was to determine whether oral etoposide and cisplatin combination (EoP) is superior to paclitaxel in the treatment of advanced breast cancer (ABC) patients pretreated with anthracyclines. From December 1997 to August 2003, 201 patients were randomised, 100 to EoP and 101 to paclitaxel arms. Four patients in each arm were ineligible. The doses of etoposide and cisplatin were 50 mg p.o. twice a day for 7 days and 70 mg m(-2) intravenously (i.v.) on day 1, respectively, and it was 175 mg m(-2) on day 1 for paclitaxel. Both treatments were repeated every 3 weeks. A median of four cycles of study treatment was given in both arms. The response rate obtained in the EoP arm was significantly higher (36.3 vs 22.2%; P=0.038). Median response duration was longer for the EoP arm (7 vs 4 months) (P=0.132). Also, time to progression was significantly in favour of the EoP arm (5.5 vs 3.9 months; P=0.003). Median overall survival was again significantly longer in the EoP arm (14 vs 9.5 months; P=0.039). Toxicity profile of both groups was similar. Two patients in each arm were lost due to febrile neutropenia. The observed activity and acceptable toxicity of EoP endorses the employment of this combination in the treatment of ABC following anthracyclines. 相似文献
86.
Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy? 总被引:3,自引:0,他引:3
Chau I Jones R Cunningham D Wotherspoon A Maisey N Norman AR Jain P Bishop L Horwich A Catovsky D 《British journal of cancer》2003,89(1):36-42
A grading system (grades 1-3) for follicular lymphoma (FL) is used in the WHO classification for lymphoid malignancies based on the absolute number of centroblasts in the neoplastic follicles. Grade 3 FL is further subdivided into 3a and 3b depending on the presence or absence of centrocytes. A total of 231 patients with FL, referred from 1970 to 2001, were identified from our prospectively maintained database. Original diagnostic materials were available for review on 215 patients and these were reclassified according to the WHO grading system. Follicular lymphoma grades 1, 2 and 3 accounted for 92, 68 and 55 patients, respectively. No significant overall survival (OS) differences were observed among FL grades 1-3 (log rank P=0.25) or between grades 3a and 3b (log rank P=0.20). No significant failure-free survival (FFS) differences were observed among FL grades 1-3 (log rank P=0.72) or between grades 3a and 3b (log rank P=0.11). First-line anthracyclines did not influence OS or FFS (log rank P=0.86, P=0.58, respectively) in patients with FL grade 3. There are long-term survivors among patients with FL grade 3 with a continuing risk of relapse. Anthracyclines did not appear to influence survival or disease relapses when given as front-line therapy in our series. The role of anthracyclines should be further evaluated in large randomised studies. 相似文献
87.
LILIAN YS GODOY JUNICHIRO FUKUSHIGE HISAJI IGARASHI AKINOBU MATSUZAKI KOHJI UEDA 《Pediatrics international》1997,39(2):188-193
The anthracyclines (ATC) have been used in the treatment of many pediatric patients with malignancies. Their use, however, has been limited by a serious and potentially irreversible cardiotoxicity. The medical records of pediatric patients with malignancies who received ATC at the Department of Pediatrics, Kyushu University, from January 1985 to December 1994 were reviewed. Among the 120 children with malignancies who received ATC, six patients (5%) developed congestive heart failure, 33 (28%) had subclinical cardiac dysfunction, whereas 81 (66%) showed no evidence of cardiac dysfunction. The incidence of ATC cardiotoxicity increased at higher cumulative doses. The earliest cardiotoxicity, however, was observed in a patient who received 180 mg/m2 unassociated with other risk factors, showing the marked individual variations in its development. Children younger than 4 years had a higher incidence of cardiotoxicity compared with those older than 4 years (P < 0.01) and are therefore more vulnerable to ATC cardiotoxicity. Because serial myocardial biopsies and stress testing are not practical in younger children, and radionuclide angiogram is rather costly and not appropriate for frequent evaluation, non-invasive tests such as echocardiography and electrocardiography (ECG) still play the main role for serial cardiac monitoring in these age groups. Radionuclide angiogram should be added as the confirmatory test modality. 相似文献
88.
89.
Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. 总被引:1,自引:1,他引:1
D Pectasides M Pectasides D Farmakis N Bountouroglou M Nikolaou M Koumpou N Mylonakis C Kosmas 《Annals of oncology》2003,14(4):537-542
BACKGROUND: The purpose of this study was to evaluate the efficacy and toxicity of oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes. PATIENTS AND METHODS: Fifty anthracycline- and taxane-pretreated MBC patients were treated with oxaliplatin 85 mg/m(2) as a 2-h infusion on day 1, LV 200 mg/m(2)/day as a 2-h infusion followed by bolus 5-FU 400 mg/m(2)/day and a 22-h infusion of 5-FU 600 mg/m(2)/day for 2 consecutive days. Treatment was repeated every 3 weeks. Patients were evaluated for response every two cycles. RESULTS: The median age was 51 years (range 34-75). Twenty patients (40%) had received three or more chemotherapeutic regimens, 64% had three or four metastatic sites and 78% had visceral metastases. All patients had prior exposure to anthracyclines and taxanes. Based on an intention-to-treat analysis, one patient (2%) achieved a complete response and 16 (32%) a partial response, for a 34% overall response rate. Twenty-one patients (42%) had stable disease and 12 (24%) progressive disease. The median time to tumor progression was 5.3 months (range 0.5-12.8) and the median overall survival was 12.3 months (range 0.5-19.2). Toxicity was mild to moderate. Grade 3/4 neutropenia and thrombocytopenia occurred in 32% and 18%, respectively. Febrile neutropenia was experienced by three patients (6%), who were successfully treated. Grade 3/4 neurotoxicity was reported in 14% of the patients and gradually declined after treatment discontinuation. Cycle delays were reported in 28% of patients and dose reductions in 26%. Alopecia, nausea-vomiting, diarrhea and mucositis were not significant. There were no treatment-related deaths. CONCLUSION: The combination of oxaliplatin plus 5-FU/LV seems to be an active regimen in patients with MBC and prior exposure to anthracyclines and taxanes with a good safety profile. The incidence of severe toxicity was quite low and the compliance of patients to the treatment was satisfactory. The results obtained with this regimen could be considered encouraging in this heavily pretreated group of breast cancer patients with a high incidence of visceral metastases. 相似文献
90.
Anna Maria Frezza MD Tarek Assi MD Salvatore Lo Vullo Eytan Ben-Ami MD Armelle Dufresne MD Kan Yonemori MD Emi Noguchi MD Brittany Siontis MD Richard Ferraro MD Pawel Teterycz MD Florence Duffaud MD Vinod Ravi MD Bruno Vincenzi MD PhD Hans Gelderblom MD PhD Maria A. Pantaleo MD Giacomo G. Baldi MD Ingrid Desar MD Alexander Fedenko MD Robert G. Maki MD Robin L. Jones MD Robert S. Benjamin MD Jean Yves Blay PhD Akira Kawai MD Mrinal Gounder MD Alessandro Gronchi MD Axel Le Cesne MD Olivier Mir MD Anna M. Czarnecka MD Scott Schuetze MD Andrew J. Wagner MD PhD Julien Adam MD Marta Barisella MD Marta Sbaraglia MD Jason L. Hornick MD PhD Alexandra Meurgey MD Luigi Mariani MD Paolo G. Casali MD Katherine Thornton MD Silvia Stacchiotti MD 《Cancer》2020,126(1):98-104